PHILLIPSBURG, N.J., May 22 /PRNewswire-FirstCall/ -- Celldex Therapeutics (a wholly-owned subsidiary of AVANT Immunotherapeutics)(Nasdaq: AVAN) announced today that its lead product candidate, CDX-110, being developed for the treatment of Glioblastoma Multiforme (GBM), will be the subject of an oral presentation at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO). The ASCO meeting will be held at McCormick Place in Chicago from May 30 through June 3, 2008.
The oral presentation, scheduled for Monday, June 2 from 10:00 - 10:15 a.m. CDT in room S406 (Vista Room), will include median survival data from ACTIVATE, a phase IIa clinical trial, and data from ACT II, the extension arm of the study. The presentation will be given by John H. Sampson, MD, PhD, Associate Professor of Neurosurgery at Duke University Medical Center.
On April 16, 2008, Pfizer, Inc. and Celldex entered into an agreement that granted Pfizer an exclusive worldwide license to CDX-110, an investigational vaccine currently in development for the treatment of GBM.
CDX-110 is designed to induce or enhance the body's immune responses against epidermal growth factor variant III (EGFRvIII) and may lead to destruction of tumor cells that express this variant receptor. A randomized Phase 2 trial is currently enrolling at 24 sites across the United States.
About Glioblastoma Multiforme
GBM is the most common form of primary brain tumor. It is an aggressive
tumor with very poor prognosis.(1) There are an estimated 10,000 new cases
of GBM annually in the United States, which predominantly affects adults
aged 45 to 70. Current GBM treatment options include surgical resection,
radiotherapy and chemotherapy.
|SOURCE AVANT Immunotherapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved